[go: up one dir, main page]

ATE394124T1 - Verfahren, zusammensetzungen und herstellungsgegenstände zur modulierung des knochenwachstums - Google Patents

Verfahren, zusammensetzungen und herstellungsgegenstände zur modulierung des knochenwachstums

Info

Publication number
ATE394124T1
ATE394124T1 AT03727927T AT03727927T ATE394124T1 AT E394124 T1 ATE394124 T1 AT E394124T1 AT 03727927 T AT03727927 T AT 03727927T AT 03727927 T AT03727927 T AT 03727927T AT E394124 T1 ATE394124 T1 AT E394124T1
Authority
AT
Austria
Prior art keywords
bone growth
methods
articles
compositions
manufacture
Prior art date
Application number
AT03727927T
Other languages
English (en)
Inventor
Itai Bab
Raphael Mechoulam
Esther Shohami
Andreas Zimmer
Original Assignee
Yissum Res Dev Co
Andreas Zimmer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co, Andreas Zimmer filed Critical Yissum Res Dev Co
Application granted granted Critical
Publication of ATE394124T1 publication Critical patent/ATE394124T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/553—Renin inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03727927T 2002-06-06 2003-06-08 Verfahren, zusammensetzungen und herstellungsgegenstände zur modulierung des knochenwachstums ATE394124T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38588102P 2002-06-06 2002-06-06
US41027602P 2002-09-13 2002-09-13

Publications (1)

Publication Number Publication Date
ATE394124T1 true ATE394124T1 (de) 2008-05-15

Family

ID=33479219

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03727927T ATE394124T1 (de) 2002-06-06 2003-06-08 Verfahren, zusammensetzungen und herstellungsgegenstände zur modulierung des knochenwachstums

Country Status (7)

Country Link
US (2) US7749953B2 (de)
EP (1) EP1509250B1 (de)
JP (1) JP2006517194A (de)
AT (1) ATE394124T1 (de)
AU (1) AU2003233172A1 (de)
DE (1) DE60320784D1 (de)
WO (1) WO2004103410A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7024027B1 (en) * 2001-11-13 2006-04-04 Koninklijke Philips Electronics N.V. Method and apparatus for three-dimensional filtering of angiographic volume data
JP2006517194A (ja) * 2002-06-06 2006-07-20 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム 骨成長を調節するための方法、組成物および製造物
MXPA05006728A (es) * 2002-12-19 2005-09-08 Merck & Co Inc Amidas sustituidas.
US7407753B2 (en) 2004-05-24 2008-08-05 Yissum Research Development Company Of The Hebrewuniversityofjerusalem Methods, kits and pharmaceutical compositions for diagnosing, delaying onset of, preventing and/or treating osteoporosis
NO20053519L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av forbindelser som omfatter fettsyrer
US20100004244A1 (en) * 2006-06-27 2010-01-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of cb2 receptor agonists for promoting neurogenesis
EP2063808A4 (de) * 2006-09-14 2012-06-13 Spineology Inc Saugfähiges faserimplantat
JP5829400B2 (ja) * 2008-01-24 2015-12-09 レメドー バイオメッド リミテッド 骨再生のためのエリスロポイエチンおよびフィブロネクチン組成物
GB0808668D0 (en) * 2008-05-13 2008-06-18 Univ Aberdeen Materials and methods relating to a G-protein coupled receptor
WO2010041253A1 (en) 2008-10-06 2010-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions comprising cb receptor agonists, uses thereof and methods for their preparation
TWI443337B (zh) * 2008-10-10 2014-07-01 Ct Hospitalier Universitaire Sainte Justine 用於脊柱側彎之分類及診斷的方法
US8541386B2 (en) * 2009-08-19 2013-09-24 University Of South Florida Cannabinoid 2 (CB2) receptor gene promoter and unique RNA transcripts in B cells and methods of use
US10413253B2 (en) * 2014-11-21 2019-09-17 Samsung Electronics Co., Ltd. Method and apparatus for processing medical image
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
KR102002817B1 (ko) * 2017-10-25 2019-07-23 주식회사 시티오브테크 방수 아스콘 첨가제 및 그 제조방법, 방수 아스콘 및 그 제조방법 그리고, 방수 아스콘 시공방법
WO2019232413A1 (en) * 2018-05-31 2019-12-05 Corbus Pharmaceuticals Inc. Cannabinoids and uses thereof
US11793452B2 (en) 2019-10-03 2023-10-24 Johnson & Johnson Consumer Inc. Method of visualizing and quantifying remineralization
KR20220138990A (ko) * 2021-04-07 2022-10-14 주식회사 스템바이오 우유 유래 세포외소포체를 포함하는 골형성 촉진용 조성물
CN114748604B (zh) * 2022-05-10 2023-04-07 四川大学 一种用于骨髓损伤和/或抑制的复合物

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5068234A (en) 1990-02-26 1991-11-26 Sterling Drug Inc. 3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles
CA2040264A1 (en) 1990-04-12 1991-10-13 Tatsuhiko Kanmera Parathyroid hormone antagonists
US5225925A (en) 1991-01-23 1993-07-06 Amoco Corporation Sensitized erbium fiber optical amplifier and source
US5208219A (en) 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
ATE139700T1 (de) 1991-02-15 1996-07-15 Takeda Chemical Industries Ltd Mit einem zellwachstumsfaktor bewirkte anregung von wachstum im knocheninneren
FR2673852B1 (fr) 1991-03-13 1994-04-15 Labinal Precision Mecanique Perfectionnements apportes aux cartouches de filtration comprenant un element filtrant constitue par une feuille plissee.
IL101927A0 (en) 1992-05-19 1992-12-30 Yissum Res Dev Co Probe for cannabinoid receptors
IL103932A (en) 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
US6352972B1 (en) 1995-06-06 2002-03-05 Marcel E. Nimni Bone morphogenetic proteins and their use in bone growth
US6352973B1 (en) 1995-06-07 2002-03-05 Osteopharm Inc. Bone stimulating factor
US6008208A (en) 1995-10-23 1999-12-28 Osteoscreen, Inc. Compositions and methods for treating bone deficit conditions
US6440421B1 (en) 1996-04-18 2002-08-27 Auchkland Uniservices Limited Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
US5688825A (en) 1996-05-31 1997-11-18 University Of Connecticut Anandamide amidase inhibitors as analgesic agents
CA2278307A1 (en) * 1997-01-21 1998-07-23 Siegfried Benjamin Christensen Iv Novel cannabinoid receptor modulators
FR2758723B1 (fr) 1997-01-28 1999-04-23 Sanofi Sa Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
DE19706903A1 (de) 1997-02-21 1998-08-27 Bayer Ag Verwendung von bekannten Agonisten des zentralen Cannabinoid-Rezeptors CB 1
CA2283797A1 (en) * 1997-03-18 1998-09-24 Paul Elliot Bender Novel cannabinoid receptor agonists
WO1999026612A1 (en) * 1997-11-21 1999-06-03 Smithkline Beecham Corporation Novel cannabinoid receptor modulators
CA2326766A1 (en) 1998-04-03 1999-10-14 Yissum Research Development Company Of The Hebrew University Of Jerusale M Synthetic endogenous cannabinoids analogues and uses thereof
ES2224658T3 (es) 1998-05-04 2005-03-01 The University Of Connecticut Nuevos canabinoides selectivos hacia el receptor cb2.
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
AU4013500A (en) 1999-07-28 2001-02-19 Ewonders.Com Dynamic data gathering markup language
EP1254115A2 (de) 2000-02-11 2002-11-06 Bristol-Myers Squibb Company Cannabinoid-rezeptor modulatoren, verfahren zu ihrer herstellung, und verwendung der cannabinoid-rezeptor modulatoren um respiratorische und nicht respiratorische krankheiten zu behandeln
US6448288B1 (en) 2000-05-17 2002-09-10 University Of Massachusetts Cannabinoid drugs
ES2227220T3 (es) 2000-06-23 2005-04-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem 2-arachidonylglycerol (2-ag) - inhibidor de factor de necrosis tumoral alfa y neuroprotector cerebral en traumatismo craneoencefalico cerrado.
FR2816938B1 (fr) * 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
US20020077322A1 (en) 2000-12-15 2002-06-20 Ayoub George S. Protection of neurons against glutamate-induced damage in glaucoma and other conditions
US20020111377A1 (en) 2000-12-22 2002-08-15 Albany College Of Pharmacy Transdermal delivery of cannabinoids
DE60234246D1 (de) * 2001-04-06 2009-12-17 Univ Illinois Cannabinoiden zur behandlung von während des schlafens auftretenden atmungsstörungen
JP2006517194A (ja) * 2002-06-06 2006-07-20 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム 骨成長を調節するための方法、組成物および製造物
EP1606019A1 (de) * 2003-03-07 2005-12-21 The University Court of The University of Aberdeen Inverse agonisten und neutrale antagonisten des cannabinoid-rezeptors als arzneimittel zur behandlung von knochenkrankheiten

Also Published As

Publication number Publication date
US20100222438A1 (en) 2010-09-02
EP1509250A1 (de) 2005-03-02
US20050137159A1 (en) 2005-06-23
EP1509250A4 (de) 2005-08-17
US7749953B2 (en) 2010-07-06
EP1509250B1 (de) 2008-05-07
JP2006517194A (ja) 2006-07-20
WO2004103410A1 (en) 2004-12-02
AU2003233172A1 (en) 2004-12-13
DE60320784D1 (de) 2008-06-19

Similar Documents

Publication Publication Date Title
ATE394124T1 (de) Verfahren, zusammensetzungen und herstellungsgegenstände zur modulierung des knochenwachstums
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
DE602004031134D1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
JO2481B1 (en) Silo cano-indol compounds have fluoride substitution and formulations containing such compounds and their treatment methods
BR0315689A (pt) Alvo para terapia de dano cognitivo
MEP90508A (en) New pharmaceutical composition
DK0725790T3 (da) Substituerede tetra- og pentapeptidinhibitorer af proteinfarnesyltransferase
DE60335743D1 (de) Verbindungen und verfahren zur erhöhung der neurogenese
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DE602005026556D1 (de) Zusammensetzung zur proteasomhemmung
ATE311363T1 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
WO2003103581A3 (en) COMPOSITIONS AND METHODS FOR LIVER GROWTH AND PROTECTION
BRPI0414598A (pt) indóis substituìdos
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
ATE448775T1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
ATE421574T1 (de) Zellkulturmethode zur erzeugung von prostata- ähnlichen acini
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
ATE423110T1 (de) Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
DE60329326D1 (de) Tace inhibitoren
EP1513397A4 (de) Transgene huftiere, die zur produktion von menschlichen antikörpern fähig sind
ATE290857T1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
ATE400552T1 (de) 4,4' -dithiobis- (3-aminobutane-1-sulfonate)- derivate und sie enthaltende zusammensetzungen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties